Intertek Expands Pharma Services Facility

Article

Intertek has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, UK, through the acquisition of a new 20,000 sq. ft facility.

Intertek, a provider of total quality assurance, has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, United Kingdom, through the acquisition of a new 20,000 sq. ft facility.

The new facility doubles the current footprint of the company’s laboratory and is under development. The newly expanded facility is expected to open towards the end of 2019 and should provide capacity for more than 100 additional employees, which the company will recruit over a four-year period, it was revealed in a May 1, 2019 press release.

This new facility is located adjacent to the company’s current good manufacturing practice (GMP) laboratory and will expand the inhalation and nasal testing resources. Additionally, it will provide a dedicated laboratory space that will focus on formulation development of inhaled biologics aimed at meeting the increasing demand from global clients. 

“We are delighted to expand and invest in inhalation and nasal product testing for biologics and pharmaceuticals at our Melbourn site, as global demand grows for specialist contract laboratory services,” said Intertek UK & Eire chief executive Rob van Dorp. “This latest expansion brings increased capacity and flexibility and will help to deliver a superior customer service for our clients around the world. Integrated with the teams’ outstanding expertise in analytical and formulation support for the pharmaceutical, biotechnology, and drug delivery industries, we can effectively help our clients to meet milestones for their challenging pharmaceutical development programmes through our systemic, end-to-end Total Quality Assurance solutions.”

Source: Intertek

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
David Fairen-Jimenez
Industry Outlook 2025: The Rising Prominence of AI in Pharma
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.